top of page

Latest News

Feb 1, 2025

Delphian Tx Won the "Editor's Choice" Award in the Journal of the International Headache Society

Being selected for Editor’s Choice underscores the originality and scientific significance of this research within the field of headache medicine.

Read More
Delphian Tx Won the "Editor's Choice" Award in the Journal of the International Headache Society

Sep 30, 2024

Delphian Tx Awarded $2.9M Phase 2 SBIR from U.S. National Institutes of Health to Advance to First in Human Trials

The $2.9M follows grant from the National Institute on Drug Abuse enables Delphian to use its Seed Financing toward a phase 1 clinical trial.

Read More
Delphian Tx Awarded $2.9M Phase 2 SBIR from U.S. National Institutes of Health to Advance to First in Human Trials

May 1, 2024

Delphian Tx Closes $2.7M Seed Round to Advance Development of S1-221 For Migraine

Delphian Tx has secured $2.7M in seed funding to advance its lead candidate, S1-221, an optimized combination of CBD:THC to treat migraine, into phase 1 clinical trials in 2025. 

Read More
Delphian Tx Closes $2.7M Seed Round to Advance Development of S1-221 For Migraine
bottom of page